title: Nasopharyngeal carcinoma in the young: a combined M.D. Anderson and Stanford experience.
abstract: From 1956 to 1988, 57 children and young adults (age 4-21 years) with a diagnosis of nasopharyngeal carcinoma were treated at The University of Texas M.D. Anderson Cancer Center (42 patients) and Stanford University Medical Center (15 patients). The male to female ratio was 2:1. Forty-three patients had lymphoepithelioma, seven had undifferentiated neoplasms, and seven had squamous cell carcinoma. Two patients had Stage III disease and the remainder had Stage IV disease at the time of presentation. All patients were treated with primary radiotherapy, and 14 patients also had chemotherapy with combinations of the following drugs: dactinomycin, doxorubicin, bleomycin, cisplatin, cyclophosphamide, fluorouracil, methotrexate, and vincristine. Twenty-six patients are alive 6 to 178 months from the first day of treatment (median 93 months). The 5- and 10-year actuarial survival rates are 51% and 36%, respectively, and the corresponding disease specific survival rates were 51% and 51%. There were no recurrences after 42 months. The patterns of failure were as follows: distant metastasis only, 21 patients; locoregional metastasis only, 1; both, 5. Distant metastases most commonly occurred in bones, lungs, liver, and mediastinal lymph nodes. Chronic treatment-related morbidity was encountered in a significant number of long term survivors. Trends in the data not reaching statistical significance suggest a more favorable prognosis for a) females, b) patients less than or equal to 15 years of age, c) lymphoepithelioma or undifferentiated histologies, d) stages T3-4 NO-1 vs T1-2 N2-3 vs T3-4 N2-3, e) primary tumor dose greater than or equal to 65 Gy and f) patients who received chemotherapy.
authors.affiliation: Department of Radiation Oncology, Stanford University Medical Center, CA.
authors.forename: L
authors.initials: L
authors.lastname: Ingersoll
authors.forename: S Y
authors.initials: SY
authors.lastname: Woo
authors.forename: S
authors.initials: S
authors.lastname: Donaldson
authors.forename: J
authors.initials: J
authors.lastname: Giesler
authors.forename: M H
authors.initials: MH
authors.lastname: Maor
authors.forename: D
authors.initials: D
authors.lastname: Goffinet
authors.forename: A
authors.initials: A
authors.lastname: Cangir
authors.forename: H
authors.initials: H
authors.lastname: Goepfert
authors.forename: M J
authors.initials: MJ
authors.lastname: Oswald
authors.forename: L J
authors.initials: LJ
authors.lastname: Peters
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate